anti-psma gamma delta t-cell engaging bispecific antibody lava-1207
Generic: Anti-PSMA Gamma Delta T-cell Engaging Bispecific Antibody LAVA-1207
anti-psma gamma delta t-cell engaging bispecific antibody lava-1207: 1 clinical trial tracked.
anti-psma gamma delta t-cell engaging bispecific antibody lava-1207 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-psma gamma delta t-cell engaging bispecific antibody lava-1207, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1 Open-label Trial to Evaluate the Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207, a PSMA-targeting Bispecific γδ-T Cell Engager, Alone or With Low Dose Interleukin-2 or Pembrolizumab, in Patients With Therapy Refractory mCRPC
Primary endpoint: Part 1 & Part 2: Frequency and severity of AEs
Interventionalopen96 targetStarted 2022-01Completion 2025-0612 sites · Netherlands, Spain, United StatesLava Therapeutics